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Objective: To evaluate the impact of intravesical prostatic protrusion (IPP) and prostatic calciﬁcation on
medical treatment for male lower urinary tract symptoms (LUTS).
Materials and methods: Men over the age of 40 years with total International Prostate Symptom Score
(IPSS)  8 were recruited from January to August 2013. The maximal ﬂow rate, postvoiding residual
(PVR) urine volume, total prostate volume (TPV), transitional zone volume (TZV), transitional zone index
(TZI), and grades of IPP and prostate calciﬁcation were recorded. All patients received a-blocker mon-
otherapy, and Global Response Assessment (GRA) was used to determine treatment response 1 month
after the treatment. The primary end point was to compare the treatment results in patients with and
without signiﬁcant IPP or prostate calciﬁcation. Univariate and multivariate logistic regression analyses
were performed to determine whether IPP and prostatic calciﬁcation are predictors of improved outcome
(GRA  1).
Results: We enrolled 112 men with a mean age of 65.5 (range, 42e89) years. IPP was signiﬁcantly
positively correlated with TPV, TZV, TZI, and PVR. Prostatic calciﬁcation was signiﬁcantly negatively
correlated with total IPSS, IPSS Voiding, and IPSS Storage. After 1-month treatment with a-blockers, the
average total IPSS decreased from 18.2 ± 7.4 to 13.1 ± 4.5. Sixty-nine patients (61.6%) reported improved
outcomes. Patients with large prostate volumes (TPV  40 mL) and small prostate volumes (TPV < 40 mL)
had similar improved outcome rates (56.5% and 65.1%, respectively). Patients with signiﬁcant IPP (Grades
II and III) had signiﬁcantly lower improved outcome rates (36.8%) than those without signiﬁcant IPP
(74.3%). Patients with prostatic calciﬁcation also had a signiﬁcantly lower rate of improved outcome
(47.9%) than those who did not (71.9%). Multivariate logistic regression analyses showed that IPP and
prostatic calciﬁcation are predictors of unfavorable outcome (GRA < 1) after adjusting for age, TPV, and
total IPSS.
Conclusion: Signiﬁcant IPP and prostatic calciﬁcation are unfavorable predictors of successful a-blocker
treatment for benign prostatic hyperplasia-induced male LUTS.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Benign prostatic hyperplasia (BPH) affects over 50% of men by
60 years of age, resulting in millions of dollars in health-care ex-
penditures for the treatment of lower urinary tract symptomsrtment of Surgery, Cardinal
ian District, New Taipei City
hiang).
ociation. Published by Elsevier Ta(LUTS) and urinary obstruction.1 The use of a-blockers is the ﬁrst-
line treatment for patients with bothersome LUTS caused by BPH,
but some patients are dissatisﬁed with initial medical treatment.
Patients with more severe symptoms and larger prostate volumes
have a higher risk of medical treatment failure. The International
Prostate Symptom Score (IPSS) and total prostate volume (TPV) are
useful predictors of medical treatment maintenance.2
Intravesical prostatic protrusion (IPP) is a morphological change
in the prostate. Patients with signiﬁcant IPP are more likely to have
decreased peak urinary ﬂow rates and to present with acute urinary
retention (AUR).3 IPP can also be used to predict the success of aiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Baseline characteristics of patients.
Mean SD
Age (y) 65.5 10.9
TPV (mL) 42.0 24.4
TZV (mL) 17.1 12.9
TZI 0.39 0.13
Qmax (mL/s) 14.5 15.5
PVR (mL) 29.1 27.5
Total IPSS 18.2 7.4
IPSS-V 10.6 5.2
IPSS-S 7.5 3.4
IPP
Grade I 74 (66.1%)
Grade II 21 (18.8%)
Grade III 17 (15.2%)
Calciﬁcation
Yes 48 (42.9%)
C.-H. Kuei et al. / Urological Science 27 (2016) 13e1614voiding trial following AUR,4 and patients with signiﬁcant IPP have
more severe bladder outlet obstruction (BOO) and impaired
detrusor function.5 Lee et al6 found that a higher IPP grade is
associated with a higher risk of clinical progression in LUTS. Male
overactive bladder may be correlated with IPP,7 and the degree of
IPP can also be associated with storage symptoms.8 Further, sig-
niﬁcant IPP may be an independent predictor of improved post-
operative outcomes.9
Multiple small calciﬁcations are often incidental ﬁndings on
prostate ultrasounds and an indicator of the aging process rather
than pathologic ﬁndings. Larger numbers of prostatic calciﬁcations
have been reported to be related to underlying inﬂammation.10
However, the role of prostatic calciﬁcation in male LUTS has not
been investigated. The objective of this study was to evaluate the
impact of IPP and prostatic calciﬁcation on medical treatment for
LUTS.No 64 (57.1%)
IPP ¼ intravesical prostatic protrusion; IPSS ¼ International Prostate Symptom
Score; IPSS-S ¼ IPSS Storage subscore; IPSS-V ¼ IPSS Voiding subscore;
PVR ¼ postvoid residual; Qmax ¼ maximal ﬂow rate; TPV ¼ total prostate volume;
TZI ¼ transitional zone index; TZV ¼ transitional zone volume; SD ¼ standard
deviation.
Table 2
Association between IPP and other parameters.
Association coefﬁcient (g)* p
Age 0.11 0.23
TPV 0.44 0.00*
TZV 0.43 0.00*
TZI 0.22 0.02*
Calciﬁcations 0.11 0.27
Qmax 0.12 0.36
PVR 0.30 0.02*
Total IPSS 0.01 0.95
IPSS-V 0.71 0.64
IPSS-S 0.12 0.44
*p < 0.05 using Spearman rank correlation.
IPP ¼ intravesical prostatic protrusion; IPSS ¼ International Prostate Symptom
Score; IPSS-S ¼ IPSS Storage subscore; IPSS-V ¼ IPSS Voiding subscore;
PVR ¼ postvoid residual; Qmax ¼ maximal ﬂow rate; TPV ¼ total prostate volume;
TZI ¼ transitional zone index; TZV ¼ transitional zone volume.2. Materials and methods
Men over the age of 40 years with a total IPSS 8 were
recruited from January 2013 to August 2013. The IPSS Voiding
(IPSS-V) and Storage (IPSS-S) subscores were recorded separately
according to the validated Chinese version of the IPSS. Each pa-
tient's baseline maximal ﬂow rate (Qmax), postvoiding residual
(PVR) urine volume, voided volume, and serum prostate-speciﬁc
antigen (PSA) levels were obtained. Patients were excluded if
they had a PSA >10 ng/mL, a history of urinary retention, uro-
dynamically proven detrusor hypoactivity, active urinary tract
infection, urinary stone, documented genitourinary cancer, pre-
vious transurethral surgery, or had taken a-blockers, anti-
muscarinic agents, or 5a-reductase inhibitors within the previous
6 months.
All men underwent transrectal ultrasound of the prostate with a
6.5-MHz probe (SSD-5000; Aloka, Chiba, Japan) by a single physi-
cian. TPV, transitional zone volume (TZV), and transitional zone
index (TZI) were calculated. IPP and prostatic calciﬁcationwere also
recorded. The IPP scorewas deﬁned by the distance between the tip
of the protrusion and the bladder neck. An IPP 5 mm was classi-
ﬁed as Grade I, 5e10 mm as Grade II, and >10 mm as Grade III.
All patients received a-blocker monotherapy (tamsulosin
0.2 mg once daily) for 12 weeks. Each patient was assessed at 4
weeks and 12 weeks after the treatment. Patients rated their
symptoms after treatment compared with their symptoms at
baseline using a validated Global Response Assessment (GRA)
questionnaire, a 7-point scale ranging from markedly worse (3)
to markedly improved (þ3).11,12 Patients with a GRA score  1 at 4
weeks after the treatment were considered as having improved
outcome and were maintained on their current medication. Pa-
tients with a GRA score <1 were then either administered com-
bined therapy or switched to another medication at the discretion
of the investigator. The primary end point of the study was to
evaluate the correlation of IPP and prostatic calciﬁcation with
outcomes 4 weeks after the treatment. The secondary end point
was to evaluate the correlation of IPP and prostatic calciﬁcation
with other parameters.
Continuous variables are represented as the mean ± standard
deviation, and numbers and percentage (%) represent categorical
data. The Chi-square test was used for categorical variables.
Spearman rank test was used to assess the correlation between the
parameters. Univariate and multivariate logistic regression ana-
lyses were performed to determine whether IPP and prostatic
calciﬁcation are predictors of treatment response. A p value <0.05
was taken to be signiﬁcant. Statistical analysis was performed using
SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA).3. Results
A total of 112 menwith a mean age of 65.5 (range, 42e89) years
were enrolled in the study. Table 1 summarizes the baseline char-
acteristics. The mean prostatic volume was 42.1 mL. Of these, 74
(66.1%), 21 (18.8%), and 17 (15.2%) patients had Grade I, Grade II, and
Grade III IPP, respectively. Thirty-eight (33.9%) patients had signif-
icant IPP (Grade II and Grade III). Forty-eight patients (42.9%) had
prostatic calciﬁcation whereas 64 patients (57.1%) did not.
When we evaluated the correlation between IPP and other pa-
rameters using the Spearman rank correlation test, IPP was
signiﬁcantly positively correlated with TPV (g ¼ 0.44), TZV
(g ¼ 0.43), TZI (g ¼ 0.22), and PVR (g ¼ 0.30: Table 2). Prostatic
calciﬁcation was signiﬁcantly negatively correlated with total IPSS
(g ¼ 0.49), IPSS-V (g ¼ 0.41), and IPSS-S (g ¼ 0.43; Table 3).
After 1 month of a-blocker treatment, the average total IPSS
decreased from 18.2 ± 7.4 to 13.1 ± 4.5. Sixty-nine patients (61.6%)
reported an improved outcome (GRA  1), whereas 43 (38.4%)
patients reported no improvement (GRA < 1; Table 4). Patients with
large prostate volumes (TPV  40 mL) and small prostate volumes
(TPV < 40 mL) had similar rates of improved outcome (56.5% and
65.1%, respectively). In contrast to TPV, patients with signiﬁcant IPP
(Grade II and Grade III) had signiﬁcantly lower rates of improved
outcome (36.8%) than those without signiﬁcant IPP (74.3%). In
addition, patients with prostatic calciﬁcation also had signiﬁcantly
Table 3
Association between prostatic calciﬁcation and other parameters.
Association coefﬁcient (g)* p
Age 0.12 0.20
TPV 0.06 0.43
TZV 0.03 0.75
TZI 0.20 0.21
Qmax 0.12 0.34
PVR 0.10 0.42
Total IPSS 0.48 0.00*
IPSS-V 0.41 0.01*
IPSS-S 0.43 0.00*
*p < 0.05 using spearman rank correlation.
IPSS ¼ International Prostate Symptom Score; IPSS-S ¼ IPSS Storage subscore; IPSS-
V ¼ IPSS Voiding subscore; PVR ¼ postvoid residual; TPV ¼ total prostate volume;
TZI ¼ transitional zone index; TZV ¼ transitional zone volume.
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prostatic calciﬁcation (71.9%; Table 4). Multivariate logistic regres-
sion analyses showed that both IPP and prostatic calciﬁcation are
predictors of unfavorable medical treatment outcomes (GRA < 1),
after adjusting for age, TPV, and total IPSS (p ¼ 0.019 and p ¼ 0.024,
respectively).
4. Discussion
The a-blockers represent the ﬁrst-line treatment for patients
with bothersome LUTS caused by BPH, but some patients have less-
than-satisfactory results with their initial medical treatment. Our
results show that signiﬁcant IPP and prostatic calciﬁcation are
unfavorable predictors of successful medical treatment with a-
blockers for male LUTS caused by BPH.
IPP assessed by transabdominal ultrasonography has been re-
ported to be a better and more reliable predictor of BOO than
prostate volume.13 Transabdominal ultrasound measurement of
prostatic volume correlates well with the transrectal measure-
ment.14 Our study shows that patients with signiﬁcant IPP tend to
have larger prostate volumes, TZV, TZI, and PVR, but not IPSS.
Prostate calciﬁcation is associated with IPSS instead of IPP. With
regard to prostate calciﬁcation, our results are similar to those of
previous studies.15 The prevalence of prostate calciﬁcationwas high
in patients complaining of LUTS.16
Other sonographic characteristics were found to be associated
with LUTS, including prostatic urethral angle, resistive index of the
capsular artery, presumed circle area ratio, prostatic urethral angle,
intraprostatic protrusion, and detrusor wall thickness.17,18 In our
study, prostate calciﬁcations were associated with LUTS, but not
IPP. Lee et al19 described twomorphologic types of IPP: trilobar and
bilobar enlargement. Prostate volume, BOO index, and bladder
compliance index were signiﬁcantly lower in the bilobar adenoma
group than in the trilobar adenoma group. However, none of them
could play the urodynamic studies role in BOO diagnosis.18Table 4
Comparisons of treatment outcomes between patients with and without large
prostate (TPV  40 mL), signiﬁcant IPP (Grade II and Grade III), and prostatic
calciﬁcation.
GRA  1 GRA < 1 p
Total patients, n (%) 69 (61.6%) 43 (38.4%)
TPV  40 mL 26 (56.5%) 20 (43.5%) 0.43
TPV < 40 mL 43 (65.1%) 23 (34.9%)
Signiﬁcant IPP (Grade II and Grade III) 55 (74.3%) 29 (25.7%) 0.001*
No signiﬁcant IPP 14 (36.8%) 24 (63.2%)
Prostatic calciﬁcation 23 (47.9%) 25 (52.1%) 0.017*
No prostatic calciﬁcation 46 (71.9%) 18 (28.1%)
*p < 0.05 using Chi-square test.
GRA ¼ Global Response Assessment; IPP ¼ intravesical prostatic protrusion;
TPV ¼ total prostate volume.The existing literature has demonstrated that signiﬁcant IPP
contributes to decreased Qmax and BOO index on urodynamics.3,13
Signiﬁcant IPP also tends to predict AUR and a higher risk of
medical treatment failure.2 Our study revealed that a-blockers may
be more effective in improving symptom scores in patients with
mild IPP than in those with moderate or severe IPP.10,13 Signiﬁcant
IPP can be regarded as a more severe form of BOO. Male patients
with moderate to severe LUTS tend to have overactive bladder
symptoms, which is correlated with IPP.7 To the best of our
knowledge, this is the ﬁrst study to demonstrate that prostate
calciﬁcation can serve as an unfavorable predictor for male LUTS.
The major limitation of our study was the lack of a placebo
group, making it impossible to eliminate the placebo effect on
treatment response. Another limitation is the small sample size. In
addition, although regression analysis showed that both IPP and
prostate calciﬁcation were signiﬁcant predictors of unfavorable
outcomes after medical treatment for male LUTS, regression to the
mean of the extreme variable may be another factor that limits the
signiﬁcance of our results.5. Conclusion
Prostatic calciﬁcation is associated with LUTS. Patients with
signiﬁcant IPP and prostatic calciﬁcation had an unfavorable
response to a-blockers.Conﬂicts of interest
The authors have no conﬂicts of interest to disclose.Sources of funding
There was no speciﬁc funding for this study.References
1. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for management
of benign prostatic hyperplasia. J Urol 2014;25:304e8.
2. Hong SJ, Ko WJ, Kim SI, Chung BH. Identiﬁcation of baseline clinical factors
which predict medical treatment failure of benign prostatic hyperplasia: an
observational cohort study. Eur Urol 2003;44:94e9. discussion 99e100.
3. Doo CK, Uh HS. Anatomic conﬁguration of prostate obtained by noninvasive
ultrasonography can predict clinical voiding parameters for determining BOO
in men with LUTS. Urology 2009;73:232e6.
4. Tan YH, Foo KT. Intravesical prostatic protrusion predicts the outcome of a trial
without catheter following acute urine retention. J Urol 2003;170:2339e41.
5. Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S. Clinical signiﬁ-
cance of intravesical prostatic protrusion in patients with benign prostatic
enlargement. Urology 2007;70:1096e9.
6. Lee LS, Sim HG, Lim KB, Wang D, Foo KT. Intravesical prostatic protrusion
predicts clinical progression of benign prostatic enlargement in patients
receiving medical treatment. Int J Urol 2010;17:69e74.
7. Kim KH, Kim YS. Correlation of male overactive bladder with intravesical
prostatic protrusion. Korean J Urol 2010;51:843e6.
8. Wee JH, Choi YS, Bae WJ, Kim SJ, Cho HJ, Hong SH, et al. Inﬂuence of intravesical
prostatic protrusion on preoperative lower urinary tract symptoms and out-
comes after 120 w high performance system laser treatment in men with
benign prostatic hyperplasia. Korean J Urol 2012;53:472e7.
9. Lee JW, Ryu JH, Yoo TK, Byun SS, Jeong YJ, Jung TY. Relationship between
intravesical prostatic protrusion and postoperative outcomes in patients with
benign prostatic hyperplasia. Korean J Urol 2012;53:478e82.
10. Geramoutsos I, Gyftopoulos K, Perimenis P, Thanou V, Liagka D, Siamblis D,
et al. Clinical correlation of prostatic lithiasis with chronic pelvic pain syn-
dromes in young adults. Eur Urol 2004;45:333e7. discussion 337e8.
11. Liao CH, Lin VC, Chung SD, Kuo HC. Therapeutic effect of a-blockers and anti-
muscarinics in male lower urinary tract symptoms based on the International
Prostate Symptom Score subscore ratio. Int J Clin Pract 2012;66:139e45.
12. Liao CH, Kuo YC, Kuo HC. Predictors of successful ﬁrst-line antimuscarinic
monotherapy in men with enlarged prostate and predominant storage
symptoms. Urology 2013;81:1030e3.
13. Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic pro-
trusion with bladder outlet obstruction. BJU Int 2003;91:371e4.
C.-H. Kuei et al. / Urological Science 27 (2016) 13e161614. Yuen JS, Ngiap JT, Cheng CW, Foo KT. Effects of bladder volume on trans-
abdominal ultrasound measurements of intravesical prostatic protrusion and
volume. Int J Urol 2002;9:225e9.
15. Yang HJ, Huang KH, Wang CW, Chang HC, Yang TK. Prostate calciﬁcation
worsen lower urinary tract symptoms in middle-aged men. Urology 2013;81:
1320e4.
16. Hong CG, Yoon BI, Choe HS, Ha US, Sohn DW, Cho YH. The prevalence and
characteristic differences in prostatic calciﬁcation between health promotion
center and urology department outpatients. Korean J Urol 2012;53:330e4.17. Bang WJ, Kim HW, Lee JY, Lee DH, Hah YS, Lee HH, et al. Prostatic urethral
angulation associated with urinary ﬂow rate and urinary symptom scores in
men with lower urinary tract symptoms. Urology 2012;80:1333e7.
18. Abdi H, Kazzazi A, Bazargani ST, Djavan B, Telegraﬁ S. Imaging in benign
prostatic hyperplasia: what is new? Curr Opin Urol 2013;23:11e6.
19. Lee SW, Cho JM, Kang JY, Yoo TK. Clinical and urodynamic signiﬁcance of
morphological differences in intravesical prostatic protrusion. Korean J Urol
2010;51:694e9.
